[
  {
    "ts": null,
    "headline": "Novo Nordisk shares jump as FDA accepts oral Wegovy application",
    "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill formulation would be the first oral GLP-1 treatment for chronic weight management in adults with obesity or overweight conditions.",
    "url": "https://finnhub.io/api/news?id=c7751ec8e6baa60179bd17828960b2d69a2967066001879807dd52acb188873a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746215316,
      "headline": "Novo Nordisk shares jump as FDA accepts oral Wegovy application",
      "id": 134204349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill formulation would be the first oral GLP-1 treatment for chronic weight management in adults with obesity or overweight conditions.",
      "url": "https://finnhub.io/api/news?id=c7751ec8e6baa60179bd17828960b2d69a2967066001879807dd52acb188873a"
    }
  },
  {
    "ts": null,
    "headline": "US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss",
    "summary": "The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.  U.S.-listed shares of Novo added to session gains and were last up 5.72% at $69.36 following the news.  Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes.",
    "url": "https://finnhub.io/api/news?id=4e2d3aa69a0af08a8126c6dbf8dcc252069c78fe3b49a5dbd80f7190e7b767e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746211263,
      "headline": "US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss",
      "id": 134204350,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.  U.S.-listed shares of Novo added to session gains and were last up 5.72% at $69.36 following the news.  Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes.",
      "url": "https://finnhub.io/api/news?id=4e2d3aa69a0af08a8126c6dbf8dcc252069c78fe3b49a5dbd80f7190e7b767e1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance",
    "summary": "Eli Lilly (NYSE:LLY) recently experienced a slight decline in share price of 1.38% over the last month. This period coincided with several key events for the company, such as earnings that showed improved sales and net income, overall financial health indicators, and research findings supporting its diabetes therapy tirzepatide. Despite these positive announcements and steady performance data, the broader market exhibited a slight gain during the same period, which suggests that Eli Lilly’s...",
    "url": "https://finnhub.io/api/news?id=b818cb127beb3b1c7e1adde44d11f03c297129239a9665de3c4db4aec6021508",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746207967,
      "headline": "Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance",
      "id": 134204351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) recently experienced a slight decline in share price of 1.38% over the last month. This period coincided with several key events for the company, such as earnings that showed improved sales and net income, overall financial health indicators, and research findings supporting its diabetes therapy tirzepatide. Despite these positive announcements and steady performance data, the broader market exhibited a slight gain during the same period, which suggests that Eli Lilly’s...",
      "url": "https://finnhub.io/api/news?id=b818cb127beb3b1c7e1adde44d11f03c297129239a9665de3c4db4aec6021508"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says Drug Tariffs Are Coming. Big Pharma Execs Can’t Figure Out How Much to Worry.",
    "summary": "The Trump administration said in mid-April to expect tariffs on drug imports in a month or so, which puts the deadline sometime in the next few weeks.",
    "url": "https://finnhub.io/api/news?id=15f4a2ff0607c6619e78dabd1dfa023a6f335354b43315ea0fc387f3657e6202",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746206340,
      "headline": "Trump Says Drug Tariffs Are Coming. Big Pharma Execs Can’t Figure Out How Much to Worry.",
      "id": 134204352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Trump administration said in mid-April to expect tariffs on drug imports in a month or so, which puts the deadline sometime in the next few weeks.",
      "url": "https://finnhub.io/api/news?id=15f4a2ff0607c6619e78dabd1dfa023a6f335354b43315ea0fc387f3657e6202"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday",
    "summary": "GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.",
    "url": "https://finnhub.io/api/news?id=363d6b0b46c581ea32db7880525b4209f660ada0563639d2ce3086237f706d2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746201345,
      "headline": "Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday",
      "id": 134201519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.",
      "url": "https://finnhub.io/api/news?id=363d6b0b46c581ea32db7880525b4209f660ada0563639d2ce3086237f706d2e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.",
    "summary": "Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.",
    "url": "https://finnhub.io/api/news?id=bfa472d333417b75e16da83efd991c9487f0ce9aafa089be3ea19927674f079e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746201180,
      "headline": "Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.",
      "id": 134204354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.",
      "url": "https://finnhub.io/api/news?id=bfa472d333417b75e16da83efd991c9487f0ce9aafa089be3ea19927674f079e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Zepbound Likely to Continue Uptake Despite CVS Decision, Truist Says",
    "summary": "Eli Lilly's (LLY) Zepbound is expected to continue uptake despite CVS Health's (CVS) decision to dro",
    "url": "https://finnhub.io/api/news?id=e100eb22e3717dd9294f239e40550ef20360e637fcf8abe6255d57d72992330e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746198759,
      "headline": "Eli Lilly's Zepbound Likely to Continue Uptake Despite CVS Decision, Truist Says",
      "id": 134204355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's (LLY) Zepbound is expected to continue uptake despite CVS Health's (CVS) decision to dro",
      "url": "https://finnhub.io/api/news?id=e100eb22e3717dd9294f239e40550ef20360e637fcf8abe6255d57d72992330e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Bounces Back. Zepbound Taking A Back Seat To Novo Nordisk's Wegovy At CVS.",
    "summary": "Eli Lilly rose Friday after topping Wall Street's first-quarter expectations.  Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred weight-loss drug.  This will begin affecting sales of Lilly's rival weight-loss drug, Zepbound, in July, Evercore ISI analyst Umer Raffat said in a report.",
    "url": "https://finnhub.io/api/news?id=3d95185e99fb869310c996e3aa5d161a9ded7b6e7bbe29daa384db72115d4535",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746195351,
      "headline": "Eli Lilly Bounces Back. Zepbound Taking A Back Seat To Novo Nordisk's Wegovy At CVS.",
      "id": 134184695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly rose Friday after topping Wall Street's first-quarter expectations.  Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred weight-loss drug.  This will begin affecting sales of Lilly's rival weight-loss drug, Zepbound, in July, Evercore ISI analyst Umer Raffat said in a report.",
      "url": "https://finnhub.io/api/news?id=3d95185e99fb869310c996e3aa5d161a9ded7b6e7bbe29daa384db72115d4535"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock sell-off was 'overreaction': Analysts",
    "summary": "Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.",
    "url": "https://finnhub.io/api/news?id=1d92741ed0cc70ab60eedcb64747100b0879a550ff7526f4506c3567591833fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746195211,
      "headline": "Eli Lilly stock sell-off was 'overreaction': Analysts",
      "id": 134204356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.",
      "url": "https://finnhub.io/api/news?id=1d92741ed0cc70ab60eedcb64747100b0879a550ff7526f4506c3567591833fa"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock sell-off was 'overrreaction': Analysts",
    "summary": "Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.",
    "url": "https://finnhub.io/api/news?id=f5ff4d04feec704d3d674885a031428eae8598a1be318bf889b688c5ce4aa480",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746195211,
      "headline": "Eli Lilly stock sell-off was 'overrreaction': Analysts",
      "id": 134184696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.",
      "url": "https://finnhub.io/api/news?id=f5ff4d04feec704d3d674885a031428eae8598a1be318bf889b688c5ce4aa480"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in Bank of America Securities 2025 Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 11:40 a.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=c143c82e6b749b6347386e96bb60c3e084fe50fbb9a8d63677a5010a6a60c6bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746194400,
      "headline": "Lilly to participate in Bank of America Securities 2025 Healthcare Conference",
      "id": 134184697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 11:40 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=c143c82e6b749b6347386e96bb60c3e084fe50fbb9a8d63677a5010a6a60c6bf"
    }
  },
  {
    "ts": null,
    "headline": "Update: Eli Lilly Brushes Off CVS Decision to Drop Zepbound Coverage",
    "summary": "(Updates with CVS Health's response in the third and fourth paragraphs and latest stock moves in the",
    "url": "https://finnhub.io/api/news?id=dc8f1fa6d2fbfdd94017e022585606ed3fb2d9adbff148b7bbc2ff484094dc88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746190316,
      "headline": "Update: Eli Lilly Brushes Off CVS Decision to Drop Zepbound Coverage",
      "id": 134184698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with CVS Health's response in the third and fourth paragraphs and latest stock moves in the",
      "url": "https://finnhub.io/api/news?id=dc8f1fa6d2fbfdd94017e022585606ed3fb2d9adbff148b7bbc2ff484094dc88"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk Stock a Buy?",
    "summary": "The market for weight loss drugs is white-hot, and competition is heating up fast.  This Danish company is already facing a powerful rival in this growing segment.  For years, Denmark-based Novo Nordisk (NYSE: NVO) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors.",
    "url": "https://finnhub.io/api/news?id=3c97a78d19b0636c537456a2d3593be368927f94946457e21e1ad3fd09f1d043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746182700,
      "headline": "Is Novo Nordisk Stock a Buy?",
      "id": 134184699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The market for weight loss drugs is white-hot, and competition is heating up fast.  This Danish company is already facing a powerful rival in this growing segment.  For years, Denmark-based Novo Nordisk (NYSE: NVO) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors.",
      "url": "https://finnhub.io/api/news?id=3c97a78d19b0636c537456a2d3593be368927f94946457e21e1ad3fd09f1d043"
    }
  },
  {
    "ts": null,
    "headline": "WHO to back use of weight-loss drugs for adults globally, raises cost issue",
    "summary": "The World Health Organizationplans to officially back the use of weight-loss drugs to treatobesity in adults for the first time, a memo reviewed by Reuterson Thursday showed, marking a shift in its...",
    "url": "https://finnhub.io/api/news?id=92642559e113638c375b127fbee4c918aae6b08e42a2cf9977086ea3b1fbee2f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746180980,
      "headline": "WHO to back use of weight-loss drugs for adults globally, raises cost issue",
      "id": 134184336,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The World Health Organizationplans to officially back the use of weight-loss drugs to treatobesity in adults for the first time, a memo reviewed by Reuterson Thursday showed, marking a shift in its...",
      "url": "https://finnhub.io/api/news?id=92642559e113638c375b127fbee4c918aae6b08e42a2cf9977086ea3b1fbee2f"
    }
  },
  {
    "ts": null,
    "headline": "Company News for May 2, 2025",
    "summary": "Companies In The News Are: CVS, LLY, CAH, ICE.",
    "url": "https://finnhub.io/api/news?id=5ae3b6d51f0db6f1f8af8a7cc2e9fb1228a79a39aca141263d097e01f6b94cbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746179880,
      "headline": "Company News for May 2, 2025",
      "id": 134184700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies In The News Are: CVS, LLY, CAH, ICE.",
      "url": "https://finnhub.io/api/news?id=5ae3b6d51f0db6f1f8af8a7cc2e9fb1228a79a39aca141263d097e01f6b94cbc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...",
    "summary": "Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and obesity treatments.",
    "url": "https://finnhub.io/api/news?id=8131d87b379a0d0a3368d9fd79c1a16610a4a8ffb74cc6d5c6052921fd476a72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746169902,
      "headline": "Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...",
      "id": 134184701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and obesity treatments.",
      "url": "https://finnhub.io/api/news?id=8131d87b379a0d0a3368d9fd79c1a16610a4a8ffb74cc6d5c6052921fd476a72"
    }
  },
  {
    "ts": null,
    "headline": "Health Rounds: Breast cancer is becoming less deadly for younger women, US study finds",
    "summary": "Young U.S. women with breast cancer are not dying from thedisease as often as a decade ago, researchers reported at...",
    "url": "https://finnhub.io/api/news?id=7087182537e5777587d3f0df5fbe427b6ffa3d3567a2e12c0be45291e7359f6d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746169200,
      "headline": "Health Rounds: Breast cancer is becoming less deadly for younger women, US study finds",
      "id": 134183025,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Young U.S. women with breast cancer are not dying from thedisease as often as a decade ago, researchers reported at...",
      "url": "https://finnhub.io/api/news?id=7087182537e5777587d3f0df5fbe427b6ffa3d3567a2e12c0be45291e7359f6d"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Amazon Tops Expectations, Issues Cautious Outlook",
    "summary": "Wall Street Breakfast Podcast: Amazon Tops Expectations, Issues Cautious Outlook",
    "url": "https://finnhub.io/api/news?id=f304db1ee2fc32d7dd1c78e402418af33cbeacca2957150ad827278c33ed22a7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746168806,
      "headline": "Wall Street Breakfast Podcast: Amazon Tops Expectations, Issues Cautious Outlook",
      "id": 134183088,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f304db1ee2fc32d7dd1c78e402418af33cbeacca2957150ad827278c33ed22a7"
    }
  },
  {
    "ts": null,
    "headline": "Q1 2025 Eli Lilly and Co Earnings Call",
    "summary": "Q1 2025 Eli Lilly and Co Earnings Call",
    "url": "https://finnhub.io/api/news?id=52d761dc7d4bf62462f106410d4360965bf421e198de2b060755db7585157845",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746167453,
      "headline": "Q1 2025 Eli Lilly and Co Earnings Call",
      "id": 134184702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Q1 2025 Eli Lilly and Co Earnings Call",
      "url": "https://finnhub.io/api/news?id=52d761dc7d4bf62462f106410d4360965bf421e198de2b060755db7585157845"
    }
  }
]